ENDRA Life Sciences (NDRA) Expected to Announce Earnings on Monday

Analysts forecast Q4 2025 earnings of ($1.23) per share and revenue of $0.10 million.

Mar. 29, 2026 at 5:34am

Got story updates? Submit your updates here. ›

ENDRA Life Sciences (NASDAQ:NDRA), a medical technology company focused on Thermoacoustic Enhanced Ultrasound (TAEUS) imaging, is expected to report its Q4 2025 financial results before the market opens on Monday, March 30th.

Why it matters

ENDRA's TAEUS technology aims to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies, making this earnings announcement an important milestone for the company's progress.

The details

Analysts expect ENDRA Life Sciences to post earnings of ($1.23) per share and revenue of $0.10 million for the quarter. The company's stock opened at $4.35 on Friday, with a market capitalization of $3.26 million, a price-to-earnings ratio of -0.16, and a beta of -0.08.

  • ENDRA Life Sciences is expected to report its Q4 2025 results before the market opens on Monday, March 30, 2026.
  • The company's Q4 2025 earnings call is scheduled for Monday, March 30, 2026 at 4:00 PM ET.

The players

ENDRA Life Sciences, Inc.

A medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS) imaging.

Ascendiant Capital Markets

An equities research firm that has issued reports on ENDRA Life Sciences stock.

Weiss Ratings

An equities research firm that has issued a 'sell (e+)' rating on ENDRA Life Sciences stock.

Got photos? Submit your photos here. ›

What they’re saying

“Ascendiant Capital Markets decreased their price objective on shares of ENDRA Life Sciences from $38.00 to $30.00 and set a 'buy' rating on the stock in a report on Monday, December 8th.”

— Ascendiant Capital Markets, Equities Research Firm

“Weiss Ratings reissued a 'sell (e+)' rating on shares of ENDRA Life Sciences in a research note on Wednesday, January 21st.”

— Weiss Ratings, Equities Research Firm

What’s next

Investors and analysts will be closely watching ENDRA Life Sciences' Q4 2025 earnings report on Monday, March 30th to gauge the company's financial performance and outlook.

The takeaway

ENDRA Life Sciences' upcoming earnings announcement will be an important milestone for the company's Thermoacoustic Enhanced Ultrasound (TAEUS) technology, which aims to improve thermal ablation procedures and other heat-based therapies. The stock's performance and analyst commentary will provide insight into the market's assessment of ENDRA's progress and future potential.